Tag: estrogen receptor alpha
-
How Inluriyo and Verzenio Deliver Dual Blockade in ESR1-Mutated Breast Cancer
Inluriyo and Verzenio target two connected drivers of ESR1-mutated breast cancer. Inluriyo degrades estrogen receptor alpha to suppress estrogen-dependent transcription, while Verzenio inhibits CDK4/6 to block downstream cell-cycle progression.